On April 30, 2024 BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, and the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world, reported the launch of a collaboration aimed at uncovering molecular mechanisms underlying IO treatment response and treatment-related toxicity in advanced cancer patients and discovering actionable blood-based biomarkers (Press release, BostonGene, APR 30, 2024, View Source [SID1234642487]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
BostonGene will analyze longitudinal blood samples from PICI’s RADIOHEAD (Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets) program, a prospective study of approximately 1,200 pan-cancer patients on standard of care immune checkpoint inhibitor treatment regimens. BostonGene’s revolutionary immunoprofiling incorporates flow cytometry and RNA-sequencing to track changes in the peripheral blood, which will be correlated with genetic variations from germline DNA testing to uncover blood-based signatures with immunotherapy response, resistance and toxicity.
"PICI’s mission-focused collaboration with BostonGene is a significant step toward unlocking the potential of blood-based biomarkers to advance personalized immunotherapy," said Tarak Mody, PhD, Chief Business Officer at PICI. "Through the generation of large multi-omic datasets and machine learning, we aim to provide the PICI Network and our partners with improved patient selection strategies and valuable insights that can accelerate discovery, target validation and clinical research."
"BostonGene’s AI-driven solutions combined with PICI’s unparalleled network of immuno-oncology expertise promise to redefine how we approach advanced cancer treatment. Together, we’re pioneering the search for blood-based biomarkers," said Nathan Fowler, MD, Chief Medical Officer at BostonGene.